Company Overview
About General Proximity
General Proximity is a Cambridge, Massachusetts-based biotechnology company — backed by Y Combinator (W20) with $16 million in Series A funding in January 2025 led by Tomales Bay Capital — pioneering induced proximity medicines that work by bringing together disease-causing proteins to trigger their degradation or modulation, representing a next-generation therapeutic modality beyond traditional small molecule inhibitors and biologics. Founded in 2020, General Proximity combines computational chemistry, medicinal chemistry, and structural biology to design molecular glues and PROTACs (proteolysis-targeting chimeras) for previously undruggable targets in oncology and other disease areas — targeting the protein degradation mechanisms that cells use naturally to eliminate aberrant proteins.
Business Model & Competitive Advantage
General Proximity's induced proximity platform addresses the fundamental limitation of conventional drug design: traditional small molecule drugs work by occupying the active site of a disease-relevant protein to block its function (enzyme inhibition, receptor antagonism) — but this approach only works for 10-15% of disease-relevant proteins that have accessible binding pockets. The remaining 85%+ are 'undruggable' by conventional methods. Induced proximity medicines (molecular glues and PROTACs) work differently — rather than blocking a protein, they recruit the cell's own protein degradation machinery (the ubiquitin-proteasome system) to tag and eliminate the disease-causing protein entirely. This catalytic mechanism (one drug molecule can degrade multiple copies of the target protein) enables sub-nanomolar efficacy at low drug doses, and the protein elimination approach provides durable target engagement that inhibition-based drugs cannot achieve. General Proximity's computational platform accelerates the design of these ternary complex-forming molecules by predicting which molecular configurations will successfully recruit the degradation machinery to the target protein.
Competitive Landscape 2025–2026
In 2025, General Proximity competes in the induced proximity, molecular glue, and protein degradation drug discovery market with C4 Therapeutics (NASDAQ: CCCC, PROTAC-based oncology, $600M raised), Arvinas (NASDAQ: ARVN, PROTAC platform, $1B+ raised), and Kymera Therapeutics (NASDAQ: KYMR, protein degradation, $700M+ raised) for precision oncology and targeted protein degradation drug development platform adoption. Tomales Bay Capital's Series A leadership reflects biotech venture conviction in the induced proximity modality. Y Combinator W20 backing (unusual for a biotech company in YC) connects General Proximity with the computational biology and AI drug discovery investment community. The 2025 strategy focuses on advancing the lead oncology programs toward IND-enabling studies, building the AI-assisted ternary complex structure prediction for accelerated molecular glue design, and expanding the disease area pipeline beyond oncology to targeted protein degradation in neurodegeneration and inflammatory diseases.
Recent Activity
View all →Key Differentiators
Emerging Innovator
General Proximity is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
S2
S2 is an AI-powered security platform focused on vulnerability discovery and attack surface management for enterprise security teams. The company's platform combines automated scanning, AI-powered ana
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Compare General Proximity with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from General Proximity? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim General Proximity Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention General Proximity vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →